⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

COAG

Hemab Therapeutics Holdings, Inc.

Healthcare · Biotechnology

34.40USD

-0.4150 (-1.19%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on COAG.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 34.40
P/E—
Dvd Ind Yld0.0%
P/B3.54
P/S—
Curr EV/T12M EBITDA-13.2
Mkt Cap (USD)1.6B
Curr EV (USD)1.2B
2)

Per Share Data

EPS T12M-53.87
DPS—
Bk Val Per Sh9.73
Rev/Sh—
Cash/Sh9.79
Curr Shares Out46.7M
FCF/Sh-2.42
3)

Cash Flow Analysis

P/CF-22.1
Curr P/FCF-22.1
CF/NI1.0
Dvd P/O—
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales—
Eff Interest Rate—
4)

Growth Potential

Dil EPS 1Y Gr—
Cap 1Y Gr-53.2%
BPS 1Y Gr—
R&D To Sales—
Retention Rate—
Rev 1Y Gr—
FCF 1Y Gr—
Assets 1Y Gr—
5)

Profitability

EBITDA-0.1B
EBIT-0.1B
Operating Margin0.0%
Pretax Margin—
Net Margin0.0%
ROA-15.9%
ROE-45.7%
ROC-18.1%
Asset Turnover—
6)

Structure

Current Ratio35.85
Quick Ratio35.48
Debt/Assets0.2%
Debt/Com Eq0.2%
Net Debt/EBITDA2.88
Tot Debt/Capital0.2%
Gross Margin0.0%
EBIT/Int Exp—

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.